12:00 AM
 | 
Jul 30, 2012
 |  BC Week In Review  |  Company News  |  Deals

Funxional, Boehringer Ingelheim deal

The companies said Boehringer will acquire exclusive, worldwide rights to Funxional's somatotaxin portfolio. The portfolio's most advanced product is FX125L, an oral small molecule somatostatin receptor 2 (SSTR2) agonist, which has...

Read the full 154 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >